2. Signaling Pathways
  3. Stem Cell/Wnt
  4. Smo
  5. Smo Antagonist

Smo Antagonist

Smo Antagonists (20):

Cat. No. Product Name Effect Purity
  • HY-16582A
    Sonidegib
    		Antagonist 99.94%
    Sonidegib (Erismodegib) is a potent and selective Smo antagonist with IC50 of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively.
  • HY-100224
    SANT-1
    		Antagonist 99.87%
    SANT-1, a potent Smo antagonist, inhibits Hedgehog signaling. SANT-1 shows IC50s of 20 nM and 30 nM in Shh-LIGHT2 and SmoA1-LIGHT2 assay, respectively.
  • HY-100535
    KAAD-Cyclopamine
    		Antagonist
    KAAD-Cyclopamine, a hedgehog signaling inhibitor, is a smoothened antagonist.
  • HY-16582
    Sonidegib diphosphate
    		Antagonist 99.73%
    Sonidegib diphosphate (Erismodegib diphosphate) is a potent and selective Smo antagonist with IC50 of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively.
  • HY-145387
    MRT-81
    		Antagonist 99.85%
    MRT-81 is a potent antagonist of human and rodent smoothened (Smo) receptors, with an IC50 value of 41 nM in the Shh-light2 cells. MRT-81 has potent hedgehog inhibiting activity. MRT-81 can be used for the research of cancer.
  • HY-13459
    PF-5274857
    		Antagonist 98.89%
    PF-5274857 is a potent, selective, orally active and brain-penetrant antagonist of Smo, with an IC50 of 5.8 nM and Ki of 4.6 nM. PF-5274857 has potential for research of tumor types including brain tumors and brain metastasis driven by an activated Hh pathway.
  • HY-100036
    MK-4101
    		Antagonist 98.23%
    MK-4101 is a Smoothened (SMO) antagonist (IC50 of 1.1 μM for 293 cells ) and also a potent inhibitor of the hedgehog pathway (IC50 of 1.5 μM for mouse cells; IC50 of 1 μM for KYSE180 oesophageal cancer cells). MK-4101 has robust antitumor activity that inhibits tumor cell proliferation and induces extensive apoptosis.
  • HY-117407
    ALLO-2
    		Antagonist 99.72%
    ALLO-2 is a potent drug-resistant Smoothened (Smo) mutant antagonist that inhibits Smo agonist Hh-Ag1.5-induced luciferase expression in TM3-Gli-Luc cells with IC50 of 6 nM.
  • HY-18287
    MRT-83
    		Antagonist 99.27%
    MRT-83 is a potent antagonist of Smo, with an IC50 in the nanomolar range. MRT-83 also blocks Hedgehog (Hh) signaling.
  • HY-18287A
    MRT-83 hydrochloride
    		Antagonist 99.60%
    MRT-83 (hydrochloride) is the potent antagonist of Smoothened (Smo) receptor. MRT-83 (hydrochloride) inhibits the Hedgehog (Hh) signaling pathway and BODIPY-cyclopamine binding to human Smo. MRT-83 (hydrochloride) has the potential for researching cancer disease.
  • HY-108507
    MRT-10
    		Antagonist 98.99%
    MRT-10 is a seven-transmembrane receptor smoothened (Smo) antagonist with an IC50 of 0.65 μM in the micromolar range in various Hedgehog (Hh) assays. MRT-10 binds to the Smo receptor at the level of the Bodipycyclopamine binding site. MRT-10 can be used for the research of cancer.
  • HY-145918
    MRT-14
    		Antagonist 98.91%
    MRT-14 is a potent antagonist of Smo. Smo is the major component involved in signal transduction of the Hedgehog (Hh) morphogens. MRT-14 has the potential for the research of several types of cancers linked to abnormal Hh signaling.
  • HY-131016
    IHR-Cy3
    		Antagonist
    IHR-Cy3 is a potent fluorescent Smo antagonist with an IC50 of 100 nM.
  • HY-110240
    IHR-1
    		Antagonist 98.05%
    IHR-1 is a cell membrane impermeable Smo antagonist.
  • HY-115566
    S1PL-IN-1
    		Antagonist
    S1PL-IN-31 (compound ) is an oral active sphingosine-1-phosphate (S1P) lyase inhibitor with the IC50 of 210 nM. S1PL-IN-31 is Smoothened receptor antagonist with the IC50 of 440 nM. S1PL-IN-31 can be used for study of experimental autoimmune encephalomyelitis.
  • HY-153499
    SMO-IN-4
    		Antagonist
    SMO-IN-4 (Compound 24) is a potent and orally active smoothened antagonist (IC50: 24 nM). SMO-IN-4 has antitumor activity.
  • HY-13459A
    PF-5274857 hydrochloride
    		Antagonist
    PF-5274857 hydrochloride is a potent, selective, orally active and brain-penetrant antagonist of Smo, with an IC50 of 5.8 nM and Ki of 4.6 nM. PF-5274857 hydrochloride has potential for research of tumor types including brain tumors and brain metastasis driven by an activated Hh pathway.
  • HY-120499
    AZD8542
    		Antagonist
    AZD8542 is an antagonist of Smoothened (SMO), playing an important role in oncology. AZD8542 is a? Hedgehog (Hh) pathway antagonist on tumor progression with an emphasis on the role of the stroma compartment.
  • HY-123752
    MS-0022
    		Antagonist
    MS-0022 is a Smoothened (SMO) antagonist. MS-0022 can inhibit the Hedgehog (Hh) signaling pathway. MS-0022 can be used in anti-tumor research.
  • HY-117903A
    MRT-92
    		Antagonist
    MRT-92 is a Smoothened (Smo) antagonist (Ki=0.7 nM) with anticancer activity. MRT-92 inhibits Hedgehog signaling pathway and rodent cerebellar granule cell proliferation by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor (IC50=0.4 nM). MRT-92 can be used in the study of cerebellar glioma.